Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035

Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768

KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer

Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene

Cartron, G., Dacheux, L., Salles, G. A., Solal‐Céligny, P., BARDOS, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,954

Cetuximab for the Treatment of Colorectal Cancer

Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904

Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor

Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694

KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

Lièvre, A., Bachet, J., Boige, V., Cayre, A., Corre, D. L., Buc, E., Ychou, M., Bouché, O., Landi, B., Louvet, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5906 · Cited by 1,485

Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma

Weng, W., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,324

Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab

Khambata-Ford, S., Garrett, C. R., Meropol, N. J., Basik, M., Harbison, C. T., Wu, S., Wong, T. W., Huang, X., Takimoto, C. H., Godwin, A. K., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5437 · Cited by 1,125

Fcγ receptors and immunomodulatory antibodies in cancer

Gálvez‐Cancino, F., Simpson, A. P., Costoya, C., Matos, I. G., Qian, D., Peggs, K. S., Litchfield, K., & Quezada, S. A. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00637-8 · Cited by 99

Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: A meta-analysis of 22 studies

Qiu, L., Mao, C., Zhang, J., Zhu, X.-D., Liao, R.-Y., Xue, K., Li, J., & Chen, Q. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.05.022 · Cited by 98

Memory-Like NK Cells: Remembering a Previous Activation by Cytokines and NK Cell Receptors

Pahl, J. H. W., Cerwenka, A., & Ni, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02796 · Cited by 99

Epidermal Growth Factor Receptor: Pathway, Therapies, and Pipeline

Goffin, J. R., & Zbuk, K. M. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.08.007 · Cited by 88

“Find Me” and “Eat Me” signals: tools to drive phagocytic processes for modulating antitumor immunity

Xiao, L., Zhang, L., Guo, C., Xin, Q., Gu, X., Jiang, C., & Wu, J. (2024) · 癌症：英文版 · doi:10.1002/cac2.12579 · Cited by 87

Translating basic mechanisms of IgG effector activity into next generation cancer therapies.

Nimmerjahn, F., & Ravetch, J. V. (2012) · Europe PMC (PubMed Central) · Cited by 85

Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients

Kim, S. T., Lee, W.-S., Lanman, R. B., Mortimer, S., Zill, O. A., Kim, S. H., Jang, K. T., Kim, S.-H., Park, S. H., Park, J. O., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5465 · Cited by 87

Fc Receptor-Dependent Mechanisms of Monoclonal Antibody Therapy of Cancer

Bakema, J. E., & van Egmond, M. (2014) · Current topics in microbiology and immunology · doi:10.1007/978-3-319-07911-0_17 · Cited by 85

Interindividual Variability of Response to Rituximab: From Biological Origins to Individualized Therapies

Cartron, G., Trappe, R. U., Solal‐Céligny, P., & Hallek, M. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1292 · Cited by 84

Myeloid cells as effector cells for monoclonal antibody therapy of cancer

Braster, R., O’Toole, T. G., & van Egmond, M. (2013) · Methods · doi:10.1016/j.ymeth.2013.06.020 · Cited by 80

Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer

Rodríguez, J., Zárate, R., Bandrés, E., Boni, V., Hernandez, A. B., Sola, J. J., Honorato, B., Bitarte, N., & García‐Foncillas, J. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.01.007 · Cited by 82

Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer

Veluchamy, J. P., Spanholtz, J., Tordoir, M., Thijssen, V. L., Heideman, D. A. M., Verheul, H. M. W., de Gruijl, T. D., & van der Vliet, H. J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157830 · Cited by 83

Antibodies to TWEAK Receptor Inhibit Human Tumor Growth through Dual Mechanisms

Culp, P., Choi, D., Zhang, Y., Yin, J., Seto, P., Ybarra, S. E., Su, M., Sho, M., Steinle, R., Wong, M. H. L., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1929 · Cited by 82

Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer

Pander, J., Gelderblom, H. A. J., Antonini, N. F., Tol, J., van Krieken, J. H., van der Straaten, T., Punt, C. J. A., & Guchelaar, H. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.03.017 · Cited by 83

Antibodies in oncology

Pillay, V., Gan, H. K., & Scott, A. M. (2011) · New Biotechnology · doi:10.1016/j.nbt.2011.03.021 · Cited by 82

Cetuximab ± chemotherapy enhances dendritic cell‐mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen‐specific cytotoxic T‐cell response in vitro

Correale, P., Botta, C., Cusi, M. G., Vecchio, M. T. D., Santi, M. M. D., Savellini, G. G., Bestoso, E., Apollinari, S., Mannucci, S., Marra, M., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26181 · Cited by 77

Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy

Trotta, A. M., Ottaiano, A., Romano, C., Nasti, G., Nappi, A. G., Divitiis, C. D., Napolitano, M., Zanotta, S., Casaretti, R., D’Alterio, C., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0184 · Cited by 78

Genotypes Affecting the Pharmacokinetics of Anticancer Drugs

den Besten-Bertholee, D., Maring, J. G., & Kuilenburg, A. B. P. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0450-z · Cited by 79

Efficacy of the Monoclonal Antibody EGFR Inhibitors for the Treatment of Metastatic Colorectal Cancer

Fakih, M., & Wong, R. (2010) · Current Oncology · doi:10.3747/co.v17is1.616 · Cited by 76

Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance

Hofmann, M. H., Mani, R., Engelhardt, H., Impagnatiello, M. A., Carotta, S., Kerenyi, M. A., Lorenzo‐Herrero, S., Böttcher, J., Scharn, D., Arnhof, H., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0789 · Cited by 76

Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies

van der Horst, H. J., Nijhof, I. S., Mutis, T., & Chamuleau, M. E. D. (2020) · Cancers · doi:10.3390/cancers12103041 · Cited by 81

The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy

Fabian, K. P., & Hodge, J. W. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.10.001 · Cited by 77

Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the “THERAPY”phase 1-2 trial

Assénat, E., Azria, D., Mollévi, C., Guimbaud, R., Tubiana-Mathieu, N., Smith, D. M., Delord, J., Samalin, E., Portales, F., Larbouret, C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3473 · Cited by 77

A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

Paz-Ares, L. G., Bálint, B., Boer, R. H. D., van Meerbeeck, J. P., Wierzbicki, R. F., SOUZA, P. D., Galimi, F., Haddad, V., Sabin, T., Hei, Y.-J., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31827ce554 · Cited by 74

Biomarker-Based Prediction of Response to Therapy for Colorectal Cancer

Ross, J. S., Torres‐Mora, J., Wagle, N., Jennings, T. A., & Jones, D. (2010) · American Journal of Clinical Pathology · doi:10.1309/ajcp2y8ktdpoaorh · Cited by 74

A Human ICAM-1 Antibody Isolated by a Function-First Approach Has Potent Macrophage-Dependent Antimyeloma Activity In Vivo

Veitonmäki, N., Hansson, M., Zhan, F., Sundberg, A., Löfstedt, T., Ljungars, A., Li, Z., Niskanen, T. M., Zeng, M., Yang, Y., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.026 · Cited by 73

Germline Genetic Variation, Cancer Outcome, and Pharmacogenetics

Coate, L. E., Cuffe, S. D., Horgan, A. M., Hung, R. J., Christiani, D. C., & Liu, G. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.2336 · Cited by 73

Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer

Fiore, F. D., Sesboüé, R., Michel, P., Sabourin, J., & Frébourg, T. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6606008 · Cited by 76

Antibody-Dependent Cellular Cytotoxicity (ADCC)

Román, R. G., Murray, J. C., & Weiner, L. M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394802-1.00001-7 · Cited by 84

FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance

Caratelli, S., Sconocchia, T., Arriga, R., Coppola, A., Lanzilli, G., Lauro, D., Venditti, A., Principe, M. I. D., Buccisano, F., Maurillo, L., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00457 · Cited by 71

Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients

Maréchal, R., Schutter, J. D., Nagy, N., Demetter, P., Lemmers, A., Deviere, J. M. E., Salmon, I. J., Tejpar, S., & Laethem, J. V. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-340 · Cited by 76

Neutralization of Prolactin Receptor Function by Monoclonal Antibody LFA102, a Novel Potential Therapeutic for the Treatment of Breast Cancer

Damiano, J. S., Rendahl, K. G., Karim, C., Embry, M. G., Ghoddusi, M., Holash, J. A., Fanidi, A., Abrams, T. J., & Abraham, J. A. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0886 · Cited by 71

Nimotuzumab: beyond the EGFR signaling cascade inhibition

Mazorra, Z., Chao, L., Lavastida, A., Sanchez, B., Ramos, M., Iznaga, N., & Crombet, T. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.04.008 · Cited by 74

Therapeutic Targeting of the Colorectal Tumor Stroma

Fridman, W. H., Miller, I. S., Sautès‐Fridman, C., & Byrne, A. T. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.09.045 · Cited by 72

Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors

Wingert, S., Reusch, U., Knackmuss, S. H. J., Kluge, M., Damrat, M., Pahl, J. H. W., Schniegler‐Mattox, U., Mueller, T., Fucek, I., Ellwanger, K., et al. (2021) · mAbs · doi:10.1080/19420862.2021.1950264 · Cited by 69

Recommendations on management of EGFR inhibitor-induced skin toxicity: A systematic review

Baas, J. M., Krens, L. L., Guchelaar, H., Ouwerkerk, J., de Jong, F. A., Lavrijsen, A. P. M., & Gelderblom, H. A. J. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.09.004 · Cited by 68

Immunotherapy utilizing the combination of natural killer- and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition

Fenerty, K. E., Padget, M., Wolfson, B., Gameiro, S. R., Su, Z., Lee, J. H., Rabizadeh, S., Soon-Shiong, P., & Hodge, J. W. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0445-4 · Cited by 68

Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials

on behalf of the Cancer Immunotherapy Trials Network (CITN), Kohrt, H. E. K., Tumeh, P. C., Benson, D., Bhardwaj, N., Brody, J., Formenti, S. C., Fox, B. A., Galon, J., June, C. H., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0118-0 · Cited by 69

Cross‐talk between pathogen recognizing Toll‐like receptors and immunoglobulin Fc receptors in immunity

van Egmond, M., Vidarsson, G., & Bakema, J. E. (2015) · Immunological Reviews · doi:10.1111/imr.12333 · Cited by 69

PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer

Stein, A., Simnica, D., Schultheiß, C., Scholz, R., Tintelnot, J., Goekkurt, E., von Wenserski, L., Willscher, E., Paschold, L., Sauer, M., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002844 · Cited by 66

Recombinant Dimeric IgA Antibodies against the Epidermal Growth Factor Receptor Mediate Effective Tumor Cell Killing

Lohse, S., Derer, S., Beyer, T. D., Klausz, K., Peipp, M., Leusen, J. H. W., van de Winkel, J. G. J., Dechant, M., & Valerius, T. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003082 · Cited by 67

Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin

Srivastava, S., Pelloso, D., Feng, H., Voiles, L., Lewis, D., Hašková, Z., Whitacre, M., Trulli, S. H., Chen, Y.-J., Toso, J. F., et al. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1403-0 · Cited by 67

Impact of Epidermal Growth Factor Receptor (EGFR) Cell Surface Expression Levels on Effector Mechanisms of EGFR Antibodies

Derer, S., Bauer, P., Lohse, S., Scheel, A. H., Berger, S., Kellner, C., Peipp, M., & Valerius, T. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1202037 · Cited by 68

Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy

Houot, R., Kohrt, H. E. K., Marabelle, A., & Levy, R. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.07.003 · Cited by 66

Highly Specific Auto-Antibodies against Claudin-18 Isoform 2 Induced by a Chimeric HBcAg Virus-Like Particle Vaccine Kill Tumor Cells and Inhibit the Growth of Lung Metastases

Klamp, T., Schumacher, J., Huber, G. C., Kühne, C., Meissner, U., Selmi, A., Hiller, T., Kreiter, S., Markl, J., Türeci, Ö., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2292 · Cited by 66

Beyond KRAS mutation status: influence of KRAScopy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients

Mekenkamp, L. J., Tol, J., Dijkstra, J. R., de Krijger, I., Vink-Börger, M. E., van Vliet, S., Teerenstra, S., Kamping, E. J., Verwiel, E. T. P., Koopman, M., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-292 · Cited by 69

Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma

Forero, A., de Vos, S., Pohlman, B. L., Pashkevich, M. A., Cronier, D. M., Dang, N. H., Carpenter, S. P., Allan, B. W., Nelson, J. G., Slapak, C. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0850 · Cited by 65

Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions

Battella, S., Cox, M. C., Santoni, A., & Palmieri, G. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.5vmr0415-141r · Cited by 71

Evidence for Linkage Disequilibrium Between FcγRIIIa-V158F and FcγRIIa-H131R Polymorphisms in White Patients, and for an FcγRIIIa-Restricted Influence on the Response to Therapeutic Antibodies

Lejeune, J., Thibault, G., Ternant, D., Cartron, G., Watier, H., & Ohresser, M. C. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.4118 · Cited by 65

Immunological off-target effects of standard treatments in gastrointestinal cancers

Duffy, A. G., & Greten, T. F. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt349 · Cited by 63

Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti‐cancer antibodies: IUPHAR Review 18

Carvalho, S., Levi‐Schaffer, F., Sela, M., & Yarden, Y. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13450 · Cited by 64

Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms

Ghesquières, H., Cartron, G., Seymour, J. F., Delfau‐Larue, M., Offner, F. C., Soubeyran, P., Perrot, A., Brice, P., Bouabdallah, R., Sonet, A., et al. (2012) · Blood · doi:10.1182/blood-2012-05-431825 · Cited by 63

Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK

Giles, A. J., Hao, S., Padget, M. R., Song, H., Zhang, W., Lynes, J. P., Sánchez, V., Liu, Y., Jung, J., Cao, X., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.130688 · Cited by 62

Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors

Egloff, A. M., & Grandis, J. R. (2009) · Journal of Oncology · doi:10.1155/2009/896407 · Cited by 64

Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients

Mazorra, Z., Lavastida, A., Concha‐Benavente, F., Valdés, A. F.-C., Srivastava, R. M., García-Bates, T. M., Esperanza, H., González, Z., González, A., Lugiollo, M., et al. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00382 · Cited by 61

A comprehensive overview of FCGR3A gene variability by full-length gene sequencing including the identification of V158F polymorphism

Mahaweni, N. M., Olieslagers, T. I., Olivares-Rivas, I., Molenbroeck, S. J. J., Groeneweg, M., Bos, G. M. J., Tilanus, M. G. J., Voorter, C. E. M., & Wieten, L. (2018) · Scientific Reports · doi:10.1038/s41598-018-34258-1 · Cited by 62

Mechanisms of Resistance to NK Cell Immunotherapy

Sordo‐Bahamonde, C., Vitale, M., Lorenzo‐Herrero, S., López‐Soto, A., & Gonzalez, S. R. (2020) · Cancers · doi:10.3390/cancers12040893 · Cited by 66

Optimizing Therapeutic Antibody Function

Kaneko, E., & Niwa, R. (2010) · BioDrugs · doi:10.2165/11537830-000000000-00000 · Cited by 63

Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy

Bebb, G. D., Smith, C. J., Rorke, S., Boland, W. K., Nicacio, L., Sukhoo, R., & Brade, A. M. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1379-9 · Cited by 60

Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer

Dahan, L., Norguet, E., Étienne-Grimaldi, M.-C., Formento, J., Gasmi, M., Nanni, I., Gaudart, J., Garcia, S., Ouafik, L., Seitz, J., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-496 · Cited by 58

Obinutuzumab

Gagez, A.-L., & Cartron, G. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000107 · Cited by 58

Neutrophils as immune effector cells in antibody therapy in cancer

Behrens, L. M., van Egmond, M., & van den Berg, T. K. (2022) · Immunological Reviews · doi:10.1111/imr.13159 · Cited by 62

Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival

Siebert, N., Jensen, C., Troschke‐Meurer, S., Zumpe, M., Jüttner, M., Ehlert, K., Kietz, S., Müller, I., & Lode, H. N. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1235108 · Cited by 59

Anti‐retroviral antibody FcγR‐mediated effector functions

Bournazos, S., & Ravetch, J. V. (2017) · Immunological Reviews · doi:10.1111/imr.12482 · Cited by 54

Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome

García‐Foncillas, J., & Díaz‐Rubio, E. (2010) · Clinical & Translational Oncology · doi:10.1007/s12094-010-0551-3 · Cited by 55

Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824)

Jochéms, C., Tritsch, S. R., Pellom, S. T., Su, Z., Soon‐Shiong, P., Wong, H. C., Gulley, J. L., & Schlom, J. (2017) · Oncotarget · doi:10.18632/oncotarget.20680 · Cited by 55

All about KRAS for clinical oncology practice: Gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer

Linardou, H., Briasoulis, E. C., Dahabreh, I. J., Mountzios, G., PAPADIMITRIOU, C. A., Papadopoulos, S., Bafaloukos, D. I., Kosmidis, P., & Murray, S. J. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.07.008 · Cited by 54

Immunological and Translational Aspects of NK Cell-Based Antitumor Immunotherapies

Shevtsov, M. A., & Multhoff, G. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00492 · Cited by 56

TP53 Mutational Status and Cetuximab Benefit in Rectal Cancer: 5-Year Results of the EXPERT-C Trial

Sclafani, F., de Castro, D. G., Cunningham, D., Wilson, S. H., Peckitt, C., Tabernero, J. M., Glimelius, B. L. G., Cervantes, A. M. R., Dewdney, A., Wotherspoon, A. C., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju121 · Cited by 54

Improving outcomes in colorectal cancer: Where do we go from here?

Cutsem, E. V., Borràs, J. M., Castells, A., Ciardiello, F., Ducreux, M. P., Haq, A., Schmoll, H., & Tabernero, J. M. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.03.026 · Cited by 57

Increasing FcγRIIa affinity of an FcγRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity

Derer, S., Glorius, P., Schlaeth, M., Lohse, S., Klausz, K., Muchhal, U. S., Desjarlais, J. R., Humpe, A., Valerius, T., & Peipp, M. (2013) · mAbs · doi:10.4161/mabs.27457 · Cited by 55

Selection of IgG Variants with Increased FcRn Binding Using Random and Directed Mutagenesis: Impact on Effector Functions

Monnet, C., Jorieux, S., Urbain, R., Fournier, N., Bouayadi, K., de Romeuf, C., Behrens, C. K., Fontayne, A., & Mondon, P. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00039 · Cited by 52

miR-143 or miR-145 overexpression increases cetuximab-mediated antibody-dependent cellular cytotoxicity in human colon cancer cells

Gomes, S. E., Simões, A. E. S., Pereira, D. M., Castro, R. E., Rodrigues, C. M. P., & Borralho, P. M. (2016) · Oncotarget · doi:10.18632/oncotarget.7010 · Cited by 52

Enhancement of Immune Effector Functions by Modulating IgG’s Intrinsic Affinity for Target Antigen

Mazor, Y., Yang, C., Borrok, M. J., Ayriss, J. E., Aherne, K., Wu, H., & Dall’Acqua, W. F. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157788 · Cited by 52

Membrane-less hybrid flow battery based on low-cost elements

Leung, P., Martin, T., Shah, A. A. S. A., Mohamed, M. R., Anderson, M. A., & Palma, J. (2016) · Journal of Power Sources · doi:10.1016/j.jpowsour.2016.11.062 · Cited by 52

Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody

Monnet, C., Jorieux, S., Souyris, N., Zaki, O., Jacquet, A., Fournier, N., Crozet, F., de Romeuf, C., Bouayadi, K., Urbain, R., et al. (2014) · mAbs · doi:10.4161/mabs.27854 · Cited by 54

Fool’s gold, lost treasures, and the randomized clinical trial

Stewart, D. J., & Kurzrock, R. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-193 · Cited by 51

An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors

Mancini, M., Gal, H., Gaborit, N., Mazzeo, L., Romaniello, D., Salame, T. M., Lindzen, M., Mahlknecht, G., Enuka, Y., Burton, D. G. A., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201708076 · Cited by 52

Germline pharmacogenomics in oncology: Decoding the patient for targeting therapy

O’Donnell, P. H., & Ratain, M. J. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.01.005 · Cited by 50

ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody

Jochéms, C., Hodge, J. W., Fantini, M. C., Tsang, K. Y., Vandeveer, A. J., Gulley, J. L., & Schlom, J. (2017) · International Journal of Cancer · doi:10.1002/ijc.30767 · Cited by 50

The Current Landscape of Antibody-based Therapies in Solid Malignancies

Shah, A., Rauth, S., Aithal, A., Kaur, S., Ganguly, K., Orzechowski, C., Varshney, G. C., Jain, M., & Batra, S. K. (2020) · Theranostics · doi:10.7150/thno.52614 · Cited by 54

Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells

Meng, F., Zhang, S., Xie, J., Zhou, Y., Wu, Q., Lu, B., Zhou, S., Zhao, X., & Li, Y. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01455-z · Cited by 53

Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines

Boero, S., Morabito, A., Banelli, B., Cardinali, B., Dozin, B., Lunardi, G., Piccioli, P., Lastraioli, S., Carosio, R., Salvi, S., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0680-0 · Cited by 49

Reduced incidence of infusion‐related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication

Siena, S., Glynne‐Jones, R., Adenis, A., Thaler, J., Preusser, P., Aguilar, E. A., Aapro, M., Loos, A. H., Esser, R., & Wilke, H. (2010) · Cancer · doi:10.1002/cncr.24945 · Cited by 50

Immune biomarkers of anti-EGFR monoclonal antibody therapy

Trivedi, S., Concha‐Benavente, F., Srivastava, R. M., Jie, H., Gibson, S. P., Schmitt, N. C., & Ferris, R. L. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu156 · Cited by 50

Affinity Maturation of B7-H6 Translates into Enhanced NK Cell–Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement

Pekar, L., Klausz, K., Busch, M., Valldorf, B., Kolmar, H., Wesch, D., Oberg, H., Krohn, S., Boje, A. S., Gehlert, C. L., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2001004 · Cited by 49

Ex Vivo Antibody-Dependent Cellular Cytotoxicity Inducibility Predicts Efficacy of Cetuximab

Taylor, R. J., Saloura, V., Jain, A. K., Goloubeva, O. G., Wong, S. J., Kronsberg, S. S., Nagilla, M., Silpino, L., de Souza, J., Seiwert, T. Y., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0188 · Cited by 48

Biomarkers of Resistance to Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer

Banck, M. S., & Grothey, A. F. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0188 · Cited by 47

Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome

Calemma, R., Ottaiano, A., Trotta, A. M., Nasti, G., Romano, C., Napolitano, M., Galati, D., Borrelli, P., Zanotta, S., Cassata, A., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-232 · Cited by 47

Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel

Ashraf, S. Q., Nicholls, A. M., Wilding, J. L., Ntouroupi, T. G., Mortensen, N., & Bodmer, W. F. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218750110 · Cited by 49

Therapeutic modulation of k-ras signaling in colorectal cancer

Krens, L. L., Baas, J. M., Gelderblom, H. A. J., & Guchelaar, H. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.05.012 · Cited by 46

Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer

Chua, W. M., Kho, P. S., Moore, M. M., Charles, K. A., & Clarke, S. J. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.07.012 · Cited by 45

Evidence of epidermal growth factor receptor expression in uveal melanoma: Inhibition of epidermal growth factor-mediated signalling by Gefitinib and Cetuximab triggered antibody-dependent cellular cytotoxicity

Amaro, A. A., Mirisola, V., Angelini, G., Musso, A., Tosetti, F., Esposito, A. I., Perri, P., Lanza, F. B., Nasciuti, F., Mosci, C., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.06.011 · Cited by 46

Personalized Medicine in Oncology: Where Have we Come From and Where are we Going?

André, F., Ciccolini, J., Spano, J., Penault-Llorca, F. M., Mounier, N., Freyer, G., Blay, J., & Milano, G. A. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.79 · Cited by 45

Epidermal Growth Factor Receptor (EGFR) Antibody-Induced Antibody-Dependent Cellular Cytotoxicity Plays a Prominent Role in Inhibiting Tumorigenesis, Even of Tumor Cells Insensitive to EGFR Signaling Inhibition

Overdijk, M. B., Verploegen, S. A. B. W., van den Brakel, J. H. N., van Bueren, J. J. L., Vink, T., van de Winkel, J. G. J., Parren, P. W. H. I., & Bleeker, W. K. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003926 · Cited by 45

Exploring the Potential of Monoclonal Antibody Therapeutics for HIV-1 Eradication

Euler, Z., & Alter, G. (2014) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2014.0235 · Cited by 46

Monoclonal antibody‐mediated killing of tumour cells by neutrophils

Heemskerk, N., & van Egmond, M. (2018) · European Journal of Clinical Investigation · doi:10.1111/eci.12962 · Cited by 49

The Neutrophil: The Underdog That Packs a Punch in the Fight against Cancer

Avtenyuk, N. U., Visser, N., Bremer, E., & Wiersma, V. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217820 · Cited by 48

Next Generation Natural Killer Cells for Cancer Immunotherapy

Rossi, F., Fredericks, N., Snowden, A., Allegrezza, M. J., & Moreno‐Nieves, U. Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.886429 · Cited by 47

Engineered Protease-resistant Antibodies with Selectable Cell-killing Functions

Kinder, M., Greenplate, A. R., Grugan, K. D., Soring, K. L., Heeringa, K., McCarthy, S. G., Bannish, G., Perpetua, M., Lynch, F., Jordan, R. E., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.486142 · Cited by 43

Association of FcγRIIa and FcγRIIa polymorphisms with clinical outcome in metastatic colorectal cancer patients (mCRC) treated with cetuximab and irinotecan

Bibeau, F., Crapez, E., Fiore, F. D., Thézenas, S., Sabourin, J., Lamy, A., Frébourg, T., Michel, P., Ychou, M., & Boissière‐Michot, F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.11004 · Cited by 23

Genetic Polymorphisms of FcγRIIa and FcγRIIIa Are Not Predictive of Clinical Outcomes after Cetuximab plus Irinotecan Chemotherapy in Patients with Metastatic Colorectal Cancer

Park, S., Hong, Y. S., Lee, J., Ryu, M., Chang, H. M., Kim, K., Ahn, Y., Na, Y.-S., Jin, D., Yu, C. S., et al. (2012) · Oncology · doi:10.1159/000335959 · Cited by 25

Role of polymorphic fc gamma receptor II/III in the efficacy of cetuximab in KRAS-NRAS-BRAF-PI3K mutated.

García‐Foncillas, J., Rodriguez, J., Boni, V., Sola, I., Honorato, B., Zárate, R., & Bandrés, E. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.4_suppl.477

Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer

Rodríguez, J., Zárate, R., Bandrés, E., Boni, V., Hernandez, A. B., Sola, J. J., Honorato, B., Bitarte, N., & García‐Foncillas, J. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.01.007 · Cited by 82

Fc gamma receptor polymorphisms and KRAS status as predictive biomarkers in patients with metastatic colorectal cancer treated with biweekly cetuximab-based salvage therapy.

Zárate, R., Bandrés, E., Rodriguez, J., Bitarte, N., Honorato, B., Boni, V., Sola, I., Ponz‐Sarvisé, M., Garzón, C., & García‐Foncillas, J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.e13523